Trial Opportunities
8 opportunities | 7 pending review | 3 high-scoring
TOTAL OPPORTUNITIES
8
PENDING REVIEW
7
1 under review
HIGH-SCORING
3
feasibility ≥ 80
TOTAL EST. REVENUE
$8.3M
ENDO-METAB-305
MetabFix Therapeutics
MetabFix Type 2 Diabetes Novel Treatment
Endocrinology • Phase PHASE_III
91
ADEQUATEAVAILABLELOW
ONCO-NOVA-401
NovaCell Therapeutics
NovaCell Immunotherapy for Advanced NSCLC
Oncology • Phase PHASE_III
88
ADEQUATEREQUIRES REALLOCLOW
CARDIO-APEX-202
ApexCardio Pharmaceuticals
ApexCardio Novel Anticoagulant for AFib
Cardiology • Phase PHASE_II
82
ADEQUATEREQUIRES REALLOCLOW
PULMO-COPD-205
RespiCare Pharma
COPD Novel Bronchodilator Study
Pulmonology • Phase PHASE_II
79
TIGHTREQUIRES REALLOCLOW
NEURO-PATH-301
NeuroPath Biosciences
NeuroPath Advanced Parkinsons Therapy
Neurology • Phase PHASE_III
76
TIGHTINSUFFICIENTLOW
ONCO-BREAST-201
OncoCare Research
Breast Cancer Targeted Therapy Phase II
Oncology • Phase PHASE_II
72
INSUFFICIENTREQUIRES REALLOCMEDIUM
NEURO-MS-204
NeuroScience Global
Multiple Sclerosis Progression Inhibitor
Neurology • Phase PHASE_II
69
INSUFFICIENTINSUFFICIENTMEDIUM
CARDIO-HEART-101
GenHeart Therapeutics
Novel Heart Failure Gene Therapy Phase I
Cardiology • Phase PHASE_I
64
TIGHTINSUFFICIENTHIGH